Physician profile
Samar Vanaik
NPI 1518245281
$4,379.22
in general payments reported to CMS, 2019-2025
30 companies · $599 in 2025
The $599 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $743 · 2020: $390 · 2021: $651 · 2022: $532 · 2023: $677 · 2024: $788 · 2025: $599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,952 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,952.26 |
| Education | $111.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,135.39 | 2019-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $410.48 | 2019-2025 | Fasenra, Breztri, Tezspire |
| United Therapeutics Corporation | $380.03 | 2019-2025 | Tyvaso, Tyvaso |
| Grifols USA, LLC | $347.04 | 2019-2024 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $270.08 | 2019-2024 | Ofev |
| Actelion Pharmaceuticals US, INC. | $218.24 | 2022-2025 | Uptravi, Opsumit |
| Genentech USA, INC. | $182.47 | 2019-2023 | Xolair |
| Merck Sharp & Dohme LLC | $174.48 | 2022-2025 | Zerbaxa, Dificid, Recarbrio |
| Insmed, INC. | $152.04 | 2019-2025 | Arikayce |
| Amgen INC. | $151.80 | 2021-2025 | Tezspire |
| Genzyme Corporation | $127.36 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $105.60 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $103.53 | 2022-2025 | Dupixent |
| Sanofi-Aventis U.S. LLC | $94.95 | 2024 | |
| Sunovion Pharmaceuticals INC. | $76.40 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $49.25 | 2019-2025 | Smartvest |
| Avadel Cns Pharmaceuticals, LLC | $42.30 | 2025 | Lumryz |
| Philips North America LLC | $41.77 | 2021-2024 | (Ak6) Vest Therapy |
| Shire North American Group INC | $39.24 | 2019 | |
| Mallinckrodt Hospital Products INC. | $38.61 | 2025 | Terlivaz |
| Bayer Healthcare Pharmaceuticals INC. | $34.74 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.05 | 2020-2021 | |
| Mylan Specialty L.P. | $31.13 | 2020-2021 | |
| Gilead Sciences, INC. | $26.94 | 2019 | |
| Mallinckrodt Enterprises LLC | $23.99 | 2019 | |
| Liquidia Technologies, INC. | $20.84 | 2025 | Yutrepia |
| Itamar Medical INC | $18.99 | 2024 | Watchpatone |
| Janssen Pharmaceuticals, INC | $17.67 | 2021 | |
| Pfizer INC. | $15.77 | 2023 | |
| Harmony Biosciences LLC | $14.04 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samar Vanaik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.